News & Updates

Topical ivermectin and encapsulated benzoyl peroxide demonstrate superior short-term efficacy compared with metronidazole in the treatment of adults with moderate-to-severe rosacea in a network meta-analysis, although encapsulated benzoyl peroxide is also associated with higher treatment discontinuation rates due to adverse events.

An online, team-based connected health (TCH) model of care does not appear to be any different than in-person care in terms of improving outcomes in patients with atopic dermatitis (AD), according to a study.

Atopic dermatitis (AD) is unlikely to be associated with reduced academic performance among teens taking national compulsory examinations, according to a study.

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.

Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Patients with treatment-refractory alopecia areata (AA) may benefit from switching between Janus kinase inhibitors (JAKis), suggests a study.

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.